Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults

Research output: Contribution to journalArticle

Abstract

The fixed-dose combination of glecaprevir (GLE), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and pibrentasvir (PIB), an NS5A inhibitor, was recently approved for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1-6 (GT-1-6) without cirrhosis or with compensated cirrhosis, and for the treatment of HCV GT-1 patients who have failed treatment with either NS5A inhibitors or NS3/4A protease inhibitors, but not both. This combination, administered over 8 or 12 weeks, has resulted in high cure rates in all six HCV genotypes, including patients with HIV coinfection. GLE/PIB was well tolerated, with the most common adverse events being headache and fatigue. GLE/PIB is recommended to be taken as three tablets (total daily dose: GLE 300 mg and PIB 120 mg) orally once daily with food. No dose adjustment is required in patients with any degree of renal impairment or in patients undergoing hemodialysis. Dose adjustment is also not required in patients with Child–Pugh A liver disease. However, the use of GLE/PIB is not recommended in patients with moderate (Child–Pugh B) or severe (Child–Pugh C) hepatic impairment.

Original languageEnglish (US)
Pages (from-to)407-421
Number of pages15
JournalDrugs of Today
Volume54
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
Protease Inhibitors
Therapeutics
Fibrosis
Genotype
Coinfection
Tablets
Fatigue
Headache
Renal Dialysis
Liver Diseases
Proteins
HIV
Kidney
Food
Liver

Keywords

  • Direct-acting antivirals
  • Fixed-dose combinations
  • Glecaprevir
  • HCV therapy
  • NS3/4A inhibitors
  • NS5A inhibitors
  • Pibrentasvir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults. / Nehra, V.; Rizza, Stacey; Temesgen, Zelalem.

In: Drugs of Today, Vol. 54, No. 7, 01.07.2018, p. 407-421.

Research output: Contribution to journalArticle

@article{512ce9f6af0e480f9467bcfb46cd4314,
title = "Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults",
abstract = "The fixed-dose combination of glecaprevir (GLE), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and pibrentasvir (PIB), an NS5A inhibitor, was recently approved for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1-6 (GT-1-6) without cirrhosis or with compensated cirrhosis, and for the treatment of HCV GT-1 patients who have failed treatment with either NS5A inhibitors or NS3/4A protease inhibitors, but not both. This combination, administered over 8 or 12 weeks, has resulted in high cure rates in all six HCV genotypes, including patients with HIV coinfection. GLE/PIB was well tolerated, with the most common adverse events being headache and fatigue. GLE/PIB is recommended to be taken as three tablets (total daily dose: GLE 300 mg and PIB 120 mg) orally once daily with food. No dose adjustment is required in patients with any degree of renal impairment or in patients undergoing hemodialysis. Dose adjustment is also not required in patients with Child–Pugh A liver disease. However, the use of GLE/PIB is not recommended in patients with moderate (Child–Pugh B) or severe (Child–Pugh C) hepatic impairment.",
keywords = "Direct-acting antivirals, Fixed-dose combinations, Glecaprevir, HCV therapy, NS3/4A inhibitors, NS5A inhibitors, Pibrentasvir",
author = "V. Nehra and Stacey Rizza and Zelalem Temesgen",
year = "2018",
month = "7",
day = "1",
doi = "10.1358/dot.2018.54.7.2828188",
language = "English (US)",
volume = "54",
pages = "407--421",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "7",

}

TY - JOUR

T1 - Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults

AU - Nehra, V.

AU - Rizza, Stacey

AU - Temesgen, Zelalem

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The fixed-dose combination of glecaprevir (GLE), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and pibrentasvir (PIB), an NS5A inhibitor, was recently approved for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1-6 (GT-1-6) without cirrhosis or with compensated cirrhosis, and for the treatment of HCV GT-1 patients who have failed treatment with either NS5A inhibitors or NS3/4A protease inhibitors, but not both. This combination, administered over 8 or 12 weeks, has resulted in high cure rates in all six HCV genotypes, including patients with HIV coinfection. GLE/PIB was well tolerated, with the most common adverse events being headache and fatigue. GLE/PIB is recommended to be taken as three tablets (total daily dose: GLE 300 mg and PIB 120 mg) orally once daily with food. No dose adjustment is required in patients with any degree of renal impairment or in patients undergoing hemodialysis. Dose adjustment is also not required in patients with Child–Pugh A liver disease. However, the use of GLE/PIB is not recommended in patients with moderate (Child–Pugh B) or severe (Child–Pugh C) hepatic impairment.

AB - The fixed-dose combination of glecaprevir (GLE), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and pibrentasvir (PIB), an NS5A inhibitor, was recently approved for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1-6 (GT-1-6) without cirrhosis or with compensated cirrhosis, and for the treatment of HCV GT-1 patients who have failed treatment with either NS5A inhibitors or NS3/4A protease inhibitors, but not both. This combination, administered over 8 or 12 weeks, has resulted in high cure rates in all six HCV genotypes, including patients with HIV coinfection. GLE/PIB was well tolerated, with the most common adverse events being headache and fatigue. GLE/PIB is recommended to be taken as three tablets (total daily dose: GLE 300 mg and PIB 120 mg) orally once daily with food. No dose adjustment is required in patients with any degree of renal impairment or in patients undergoing hemodialysis. Dose adjustment is also not required in patients with Child–Pugh A liver disease. However, the use of GLE/PIB is not recommended in patients with moderate (Child–Pugh B) or severe (Child–Pugh C) hepatic impairment.

KW - Direct-acting antivirals

KW - Fixed-dose combinations

KW - Glecaprevir

KW - HCV therapy

KW - NS3/4A inhibitors

KW - NS5A inhibitors

KW - Pibrentasvir

UR - http://www.scopus.com/inward/record.url?scp=85051188597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051188597&partnerID=8YFLogxK

U2 - 10.1358/dot.2018.54.7.2828188

DO - 10.1358/dot.2018.54.7.2828188

M3 - Article

C2 - 30090878

AN - SCOPUS:85051188597

VL - 54

SP - 407

EP - 421

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 7

ER -